<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-157399" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Arcilla</surname>
            <given-names>Cristine K.</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singla</surname>
            <given-names>Ramit</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cristine Arcilla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ramit Singla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-157399.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections&#x000a0;(PANDAS) involve the sudden onset of neuropsychiatric symptoms, including obsessions, compulsions, and various tics. These conditions are characterized by the rapid development of severe behavioral symptoms in children triggered by infections, particularly streptococcal infections.&#x000a0;PANDAS is a rare autoimmune&#x000a0;disorder that was first described in 1998 by Swedo et al, and is characterized by the sudden onset of obsessive-compulsive or tic disorder symptoms following group A streptococcus infection.<xref ref-type="bibr" rid="article-157399.r1">[1]</xref><xref ref-type="bibr" rid="article-157399.r2">[2]</xref><xref ref-type="bibr" rid="article-157399.r3">[3]</xref><xref ref-type="bibr" rid="article-157399.r4">[4]</xref><xref ref-type="bibr" rid="article-157399.r5">[5]</xref>&#x000a0;PANDAS is&#x000a0;typically diagnosed in certain pediatric and prepubertal populations who have had a recent or currently have a group A beta-hemolytic streptococcus infection.<xref ref-type="bibr" rid="article-157399.r1">[1]</xref><xref ref-type="bibr" rid="article-157399.r6">[6]</xref>&#x000a0;</p>
        <p>PANDAS was initially categorized under postinfectious syndromes and defined as pediatric infection-triggered autoimmune neuropsychiatric disorders. Later, in 2010, these disorders were reclassified as pediatric acute-onset neuropsychiatric syndromes (PANS).<xref ref-type="bibr" rid="article-157399.r7">[7]</xref><xref ref-type="bibr" rid="article-157399.r8">[8]</xref><xref ref-type="bibr" rid="article-157399.r9">[9]</xref><xref ref-type="bibr" rid="article-157399.r10">[10]</xref><xref ref-type="bibr" rid="article-157399.r11">[11]</xref><xref ref-type="bibr" rid="article-157399.r12">[12]</xref>&#x000a0;PANS encompass acute-onset cases with obsessions, compulsions, and heterogeneous tics not solely triggered by infections but by other factors (eg, environmental factors, emotional stress, or exposure to oxidative toxins). PANS may involve severe eating restrictions in addition to at least 2 severe neuropsychiatric symptoms, including choreiform movements, sensory disturbances, and even hallucinations.<xref ref-type="bibr" rid="article-157399.r13">[13]</xref><xref ref-type="bibr" rid="article-157399.r14">[14]</xref>&#x000a0;PANS may also include somatic symptoms, ranging from sleep-related motor disruptions to mydriasis, enuresis, and urinary dysfunction.<xref ref-type="bibr" rid="article-157399.r12">[12]</xref>&#x000a0;The classification of PANDAS and PANS as distinct clinical entities is debated. Some theories suggest that PANDAS may be a variant of Sydenham chorea due to overlapping features and genetic predispositions.&#x000a0;</p>
        <p>Physical symptoms of PANDAS can include tics, sensitivity to sensory inputs, motor skill deterioration, sleep disorders, and joint pain; &#x000a0;psychological symptoms can encompass obsessive-compulsive behaviors, anxiety, emotional lability, developmental regression, and depression. The diagnosis of PANDAS relies on clinical criteria, including the presence of obsessive-compulsive disorders or tic disorders, sudden onset of symptoms in childhood, episodic symptom course, association with streptococcal infection, and neurological abnormalities. Despite being a diagnosis of exclusion, prompt identification and management are crucial for patient outcomes. Comprehensive diagnostic evaluation includes psychoneurological assessments, infectious disease testing, autoimmune and endocrine evaluations, imaging,&#x000a0;and genetic tests.&#x000a0;</p>
        <p>Confirmation of streptococcal infection involves throat cultures and antibody tests, though these are not definitive markers for PANDAS.&#x000a0;Neuroimaging in PANDAS patients often reveals basal ganglia abnormalities and can help distinguish PANDAS from other conditions. Treatment primarily involves antibiotics to address streptococcal infections, with &#x003b2;-lactams and macrolides being common choices. These antibiotics also have immunomodulatory, neuroprotective, and anti-inflammatory properties. Antibiotic prophylaxis and potential vaccinations against streptococcal infections are also being explored to prevent recurrence and manage symptoms.&#x000a0;Overall, understanding the epidemiology, neuropathophysiology, diagnosis, and treatment of PANDAS is essential for improving patient care and outcomes in this rare and complex condition.</p>
      </sec>
      <sec id="article-157399.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Most PANS cases reveal that more than half of patients are associated with streptococcus infection, the same causal agent of Sydenham chorea. Hence, studies have disputed PANDAS/PANS as a definite clinical entity and theorized that PANDAS is just a mild type or variant of Sydenham chorea due to overlapping clinical manifestations and a shared genetic predisposition to this condition.<xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r8">[8]</xref><xref ref-type="bibr" rid="article-157399.r15">[15]</xref><xref ref-type="bibr" rid="article-157399.r16">[16]</xref><xref ref-type="bibr" rid="article-157399.r17">[17]</xref>&#x000a0;However, some study results have mentioned differences in age groups and vulnerability windows to poststreptococcal sequelae between these diseases. Other infections that could be related to pediatric infection-triggered autoimmune neuropsychiatric disorders and PANS include <italic toggle="yes">Mycoplasma pneumoniae</italic>, <italic toggle="yes">Borrelia burgdorferi</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, herpes simplex, Epstein&#x02013;Barr virus, influenza, coxsackie virus,severe acute respiratory syndrome coronavirus 2, and varicella-zoster virus.<xref ref-type="bibr" rid="article-157399.r3">[3]</xref><xref ref-type="bibr" rid="article-157399.r17">[17]</xref>&#x000a0;Studies have also observed patients with PANS demonstrating processing speed, visual-motor, visuospatial integration, and memory deficits that could be related to cortico-subcortical network dysfunction.<xref ref-type="bibr" rid="article-157399.r3">[3]</xref><xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r10">[10]</xref><xref ref-type="bibr" rid="article-157399.r11">[11]</xref></p>
      </sec>
      <sec id="article-157399.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PANDAS lacks large-scale epidemiological studies to accurately determine its prevalence. PANDAS affects males more frequently than females, particularly boys between 3 and 12, with a mean age of 6.33 years (&#x000b1; 1.6 years). Additionally, first-degree relatives were described in more than half of all PANS cases.<xref ref-type="bibr" rid="article-157399.r13">[13]</xref>&#x000a0;Risk factors for the onset of PANDAS syndrome include multiple recurrences of group A streptococcal infections and a family history of autoimmune disease or rheumatic fever, especially on the maternal side.<xref ref-type="bibr" rid="article-157399.r8">[8]</xref><xref ref-type="bibr" rid="article-157399.r17">[17]</xref></p>
      </sec>
      <sec id="article-157399.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Several study results have described potential immune dysregulation associated with the pathophysiology of PANDAS, but the exact mechanism is still unknown.</p>
        <p>
<bold>Molecular Mimicry</bold>
</p>
        <p>A widely accepted hypothesis regarding the&#x000a0;pathophysiology of PANDAS is molecular mimicry, similar to the well-established Sydenham chorea in rheumatic fever. Molecular mimicry occurs when antigens from pathogens are similar to host antigens in sequence and structure. Recent study results demonstrated that passive transfer of streptococcus-induced antibodies in mouse models produces neuropsychiatric symptoms of PANDAS.<xref ref-type="bibr" rid="article-157399.r4">[4]</xref>&#x000a0;Antibodies are produced against streptococcal proteins, such as N-acetyl-beta D-glucosamine, a streptococcal group A carbohydrate epitope.</p>
        <p>
<bold>Central Nervous System Pathophysiology</bold>
</p>
        <p>These streptococcus-induced antibodies cross the blood-brain barrier when its permeability is compromised by infectious or noninfectious triggers, causing circulating immunoglobulin G and CD4+ T cells to enter the brain.<xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r18">[18]</xref>&#x000a0;They bind and cross-react with neuronal proteins in the brain, specifically lysoganglioside and dopamine D2 receptors, as seen in mouse models, leading to similar neuropsychiatric symptoms when these receptors are targeted.<xref ref-type="bibr" rid="article-157399.r1">[1]</xref>&#x000a0;This process results in microglial activation, with increased levels and signaling activation of calcium-calmodulin-dependent protein kinase II by monoclonal antibodies or cytoplasmic &#x003b1;-helical protein tubulin.&#x000a0;An excess dopamine synthesis and subsequent loss of excitatory synaptic proteins occur, especially in the basal ganglia, thalamus, and cerebellum in the acute phase of PANDAS.<xref ref-type="bibr" rid="article-157399.r1">[1]</xref><xref ref-type="bibr" rid="article-157399.r3">[3]</xref><xref ref-type="bibr" rid="article-157399.r4">[4]</xref><xref ref-type="bibr" rid="article-157399.r19">[19]</xref>&#x000a0;</p>
        <p>
<bold>Biologic Markers</bold>
</p>
        <p>However, the biological link between infection and the onset of symptoms in the absence of biological markers is still limited and conflicting.<xref ref-type="bibr" rid="article-157399.r20">[20]</xref>&#x000a0;Several studies have collected cerebrospinal fluid (CSF) analyses with PANDAS for the possible presence of specific antibodies in the brains of patients with PANDAS. Biologic markers could lead to more accurate diagnosis, monitoring of symptom severity, and precise and tailored therapy.<xref ref-type="bibr" rid="article-157399.r2">[2]</xref>&#x000a0;Markers such as antistreptolysin O, anti-deoxyribonucleic acid-ase B, and C-reactive protein did not show significant differences in PANDAS compared to other etiologies.</p>
        <p>
<bold>Antineuronal Antibodies</bold>
</p>
        <p>Other proposed biomarkers for PANDAS include antineuronal antibodies found in Sydenham chorea, including the D1 and D2 dopamine receptors, calcium-calmodulin-dependent protein kinase II activity, &#x003b2;-tubulin, and lysoganglioside-GM1, which are assessed commercially through the Cunningham Panel.<xref ref-type="bibr" rid="article-157399.r2">[2]</xref><xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r8">[8]</xref><xref ref-type="bibr" rid="article-157399.r15">[15]</xref><xref ref-type="bibr" rid="article-157399.r16">[16]</xref>&#x000a0;Some study results have demonstrated at least 1 positive antineuronal autoantibody elevated abnormally in both serum and CSF in patients with PANDAS.<xref ref-type="bibr" rid="article-157399.r6">[6]</xref>&#x000a0;Anti-neuronal autoantibody titers in the serum were higher than in the CSF in patients with PANDAS. This study also showed that anti-neuronal antibody levels are not typically detected in the CSF of healthy individuals. These autoantibodies were found to decrease to normal or even negative levels at 6 months follow-up, with improvement observed in more than 80% of patients with PANDAS. However, data regarding the utility of antineuronal autoantibody titers are still inconclusive and inconsistent, as these titers have poor specificity (approximately 10%) and variable negative predictive values (44% to 74%) regarding their association with PANDAS.<xref ref-type="bibr" rid="article-157399.r2">[2]</xref></p>
        <p>
<bold>Additional Proposed Theories</bold>
</p>
        <p>Some studies have theorized that the degree of neuroimmunepathogenic response depends on an individual's altered and dysregulated immunogenicity, involving specific human leukocyte antigens, type of T response, regulatory T cell response, and cytokines. Other theories propose the&#x000a0;contribution of specificity, affinity, and concentration of the autoantibodies and immunoglobulins, CSF oligoclonal bands, and immune-associated genes with the key role of Th17 cellular response.<xref ref-type="bibr" rid="article-157399.r4">[4]</xref><xref ref-type="bibr" rid="article-157399.r18">[18]</xref>&#x000a0;These autoantibodies could be induced by other pathogens with the same cellular response (eg, influenza virus, mycoplasma, and <italic toggle="yes">Staphylococcus aureus)</italic>&#x000a0;and produce clinical exacerbations. The findings of these studies support the observation that less than 25% of patients with flare-ups have group A beta-hemolytic streptococcus infection and a good response to antibiotics.</p>
      </sec>
      <sec id="article-157399.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>PANDAS syndrome is a diagnosis of exclusion based on the clinical presentation.<xref ref-type="bibr" rid="article-157399.r1">[1]</xref><xref ref-type="bibr" rid="article-157399.r15">[15]</xref>&#x000a0;Excluding other medical conditions, including autoimmune and autoinflammatory diseases, immunodeficiency syndromes, neurological disorders, and psychiatric disorders, through a complete diagnostic evaluation is critical.<xref ref-type="bibr" rid="article-157399.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Diagnostic Evaluation</bold>
</p>
        <p>Psychoneurological assessment, evaluation for infectious, autoimmune, and endocrine diseases, assessment of somatic symptoms including polysomnography or sleep evaluation, and paraneoplastic evaluation should be part of the evaluation. Assessment of specific organ systems, including cardiac testing (eg, electrocardiogram and echocardiography), CSF analyses, electroencephalogram, and neuroimaging evaluation, is crucial.<xref ref-type="bibr" rid="article-157399.r2">[2]</xref><xref ref-type="bibr" rid="article-157399.r3">[3]</xref><xref ref-type="bibr" rid="article-157399.r8">[8]</xref>&#x000a0;Genetic evaluation could also aid in assessing patient predisposition to PANDAS.</p>
        <p>
<bold>Diagnostic Criteria</bold>
</p>
        <p>Neuropsychiatric symptoms typically occur approximately 4 to 6 weeks following a streptococcal infection, with symptoms worsening and peaking within 2 to 3 days. The following criteria have been proposed to guide PANDAS diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of obsessive-compulsive or tic disorder</p>
          </list-item>
          <list-item>
            <p>Symptom onset during childhood to puberty (ie, between 3 and 12 years)</p>
          </list-item>
          <list-item>
            <p>Acute or subacute, sudden onset of symptoms with periodic exacerbation or worsening of existing symptoms for a short period (ie, relapsing and remitting episodes)</p>
          </list-item>
          <list-item>
            <p>Temporal association between confirmed streptococcal infection and onset or exacerbation of symptoms, confirmed by culture or the presence of antistreptococcal antibodies</p>
          </list-item>
          <list-item>
            <p>Association with neuropsychiatric symptoms, especially hyperactivity, choreiform motor movements, bedwetting, anxiety, emotional lability, developmental regression, or mood changes</p>
          </list-item>
        </list>
        <p>
<bold>Physical Symptoms</bold>
</p>
        <p>Physical symptoms may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tics and unusual movements</p>
          </list-item>
          <list-item>
            <p>Sensitivity to light, sound, and touch</p>
          </list-item>
          <list-item>
            <p>Deterioration of motor abilities, eg, handwriting, hyperactivity, or inability to concentrate</p>
          </list-item>
          <list-item>
            <p>Memory problems, sleep disorders</p>
          </list-item>
          <list-item>
            <p>Refusal to eat leading to weight loss</p>
          </list-item>
          <list-item>
            <p>Joint pain</p>
          </list-item>
          <list-item>
            <p>Frequent urination</p>
          </list-item>
          <list-item>
            <p>Enuresis</p>
          </list-item>
          <list-item>
            <p>Approaching a catatonic state</p>
          </list-item>
        </list>
        <p>
<bold>Psychological Symptoms</bold>
</p>
        <p>Psychological symptoms may include behavioral, anxiety, and emotional disorders, eg, repetitive, obsessive-compulsive behaviors, separation anxiety, fear, panic attacks, incessant screaming, emotional and developmental regression, visual or auditory hallucinations, irritability, frequent mood changes, depression, and suicidal thoughts.</p>
      </sec>
      <sec id="article-157399.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Defined diagnostic clinical and immunological criteria, along with characteristic phenotypes among patients with PANDAS, have not been established. However, laboratory studies to confirm streptococcal infection and neuroimaging studies are frequently utilized.<xref ref-type="bibr" rid="article-157399.r2">[2]</xref><xref ref-type="bibr" rid="article-157399.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Streptococcal Infection</bold>
</p>
        <p>Confirmation of streptococcal pharyngitis includes correctly performed throat cultures or rapid antigen tests. Cultures taken from other involved sites (eg, nasal cavity, skin and skin structures, and perianal or vaginal areas) should be conducted accordingly.<xref ref-type="bibr" rid="article-157399.r8">[8]</xref>&#x000a0;One cohort found antistreptolysin O and anti-deoxyribonucleic acid-ase B antibody titers to be positive in all PANDAS patients but negative in patients with PANS.<xref ref-type="bibr" rid="article-157399.r9">[9]</xref>&#x000a0;However, pharyngeal swabs and antistreptococcal antibodies are not considered markers of PANDAS. Positivity for these antibodies could indicate streptococcal exposure but does not distinguish a new acute infection from a chronic carrier state lasting for years.<xref ref-type="bibr" rid="article-157399.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold>Neuroimaging</bold>
</p>
        <p>One study proposes a pilot neuroimaging diagnostic protocol that can be prospectively used to compare and confirm the diagnosis of patients with PANS and PANDAS against other differential diagnoses, including obsessive-compulsive disorders, central nervous system vasculitis, Sydenham chorea, and autoimmune encephalitis. Magnetic resonance imaging of the brain has shown an enlargement of basal ganglia structures (eg, caudate nuclei, putamen, and globus pallidus) in patients with PANDAS.<xref ref-type="bibr" rid="article-157399.r15">[15]</xref><xref ref-type="bibr" rid="article-157399.r17">[17]</xref>&#x000a0;Positron emission tomography (PET) imaging and messenger ribonucleic acid analysis of post-mortem specimens from affected individuals have also shown bilateral inflammation in the basal ganglia in PANDAS patients.<xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r15">[15]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-157399.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>PANDAS treatment recommendations are debated due to a lack of consensus in the literature.<xref ref-type="bibr" rid="article-157399.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold>Antibiotic Therapy</bold>
</p>
        <p>According to the National Institute of Mental Health and the PANS/PANDAS Consortium, the primary therapeutic approach for acute episodes of PANDAS and PANS should involve an initial course of antibiotic therapy. Either &#x003b2;-lactams or macrolides are used to eradicate streptococcal infection alongside symptomatic treatment. Initiation of antibiotic treatment in all PANS cases, even without documented infections, was suggested in one study.<xref ref-type="bibr" rid="article-157399.r11">[11]</xref>&#x000a0;The efficacy of antibiotics in PANDAS and PANS lies in their direct effect against group A streptococcus infection and in their immunomodulatory and neuroprotective properties.&#x000a0;</p>
        <p>&#x003b2;-lactam molecules, including cephalosporins (eg, ceftriaxone and cefdinir) and penicillins, possess neuroprotective abilities. This modulates astroglia and microglia and&#x000a0;minimizes glutamate neurotoxicity.&#x000a0;The immunomodulatory effects of antibiotics facilitate serotonin or dopamine release and inhibit &#x003b3;-aminobutyric acid (GABA)-A receptors in a dose-dependent manner.&#x000a0;Macrolides (eg, azithromycin) act as immunomodulators, particularly in chronic inflammatory diseases. Macrolides modulate innate immunity and act on GABA-A receptors while reducing toll-like receptor 4 and interleukin 12.&#x000a0;Additionally, the antioxidant and anti-inflammatory capabilities of antibiotics help to downregulate reactive oxygen. Results from studies in rats with PANDAS and group A beta-hemolytic streptococcus infection found that ampicillin prevented dysfunction by decreasing immunoglobulin G deposition in the brain and increasing levels of tyrosine hydroxylase.<xref ref-type="bibr" rid="article-157399.r4">[4]</xref>&#x000a0;Clavulanate, a &#x003b2;-lactamase inhibitor used with amoxicillin, crosses the blood-brain barrier and exhibits antidepressant and anxiolytic properties by reducing glutamate.</p>
        <p>
<bold>Antibiotic Prophylaxis</bold>
</p>
        <p>Some studies advocate antibiotic prophylaxis against streptococcal infection, particularly in cases with a complicated course of illness manifesting severe or recurrent exacerbations of neuropsychiatric symptoms&#x000a0;similar to rheumatic fever and its complications (eg, Sydenham chorea).<xref ref-type="bibr" rid="article-157399.r4">[4]</xref><xref ref-type="bibr" rid="article-157399.r9">[9]</xref>&#x000a0;A cohort study revealed that prophylaxis with benzathine benzylpenicillin for at least 5 years in patients with PANDAS or PANS showed reduced neurological symptoms.<xref ref-type="bibr" rid="article-157399.r9">[9]</xref>&#x000a0;However, the long-term use of low-dose antibiotics in PANDAS or PANS and its potential benefits remain largely unknown.&#x000a0;Antibiotic resistance to group A streptococcus infection poses a potential threat that could lead to significant complications if PANDAS is left untreated. Appropriate monitoring should be provided to all high-risk patients.</p>
        <p>
<bold>Vaccinations</bold>
</p>
        <p>Vaccinations against group A streptococcus infection are also being studied for their potential benefits as prophylaxis against PANDAS.</p>
      </sec>
      <sec id="article-157399.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diagnosing PANDAS involves excluding various other conditions that cause similar symptoms. PANDAS is a diagnosis of exclusion, meaning other potential causes must be eliminated first. Eliminating other medical conditions, including autoimmune and autoinflammatory diseases, immunodeficiency syndromes, neurological disorders, and psychiatric disorders, through a comprehensive diagnostic evaluation is critical. Differential diagnoses also include obsessive-compulsive disorder, Tourette syndrome, other tic disorders, anxiety disorders, central nervous system vasculitis, Sydenham chorea, autoimmune encephalitis including Hashimoto disease with psychiatric features, schizophrenia, neuromyelitis optica spectrum disorder, other demyelinating diseases, infectious diseases, endocrine diseases, hormonal deficiencies, and dysfunctions. Additionally, conditions like Wilson disease and Lyme neuroborreliosis, which are known for their neuropsychiatric symptoms, should be considered in selected cases.&#x000a0;</p>
      </sec>
      <sec id="article-157399.s9" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>
<bold>Psychotherapy</bold>
</p>
        <p>Some studies have mentioned selective serotonin reuptake inhibitors (eg, fluoxetine, fluvoxamine, sertraline, and paroxetine), cognitive-behavioral therapy, and exposure response prevention as methods used to manage obsessive-compulsive disorder (OCD) and other severe psychiatric symptoms in patients with PANDAS. However, these studies were inconclusive when comparing the efficacy of these methods with that of a placebo.</p>
        <p>
<bold>Immunomodulatory Therapy</bold>
</p>
        <p>Additionally, some studies have investigated the potential role and benefits of immunomodulatory therapies in cases of PANDAS refractory to antibiotics and cognitive-behavioral therapy.&#x000a0;Additionally, investigations are underway to identify diagnostic and therapeutic biomarkers defining patients with PANDAS likely to respond well to immunomodulatory interventions.<xref ref-type="bibr" rid="article-157399.r19">[19]</xref></p>
        <p>
<bold>Steroids</bold>
</p>
        <p>Corticosteroids have been shown to improve OCD symptoms but worsen tics and may lead to relapse upon discontinuation; therefore, they are not typically recommended in PANDAS treatment.</p>
        <p>
<bold>Intravenous Immunoglobulin</bold>
</p>
        <p>Intravenous immunoglobulin therapy has shown promise in treating PANDAS by reducing OCD symptoms and improving behavior, although further research is needed to confirm its efficacy and establish optimal treatment protocols. Despite some conflicting results, intravenous immunoglobulin remains a recommended treatment for PANDAS, with study results suggesting potential long-term benefits.</p>
        <p>
<bold>Therapeutic Plasma Exchange</bold>
</p>
        <p>Therapeutic plasma exchange or plasmapheresis has also been employed in severe and refractory cases of PANDAS, particularly in patients exhibiting symptoms of suicidality and violent behaviors. According to the 2019 American Society for Apheresis guidelines, therapeutic plasma exchange, which involves the removal of antineuronal antibodies in symptomatic patients with PANDAS or PANS, is reserved as a second-line therapy.<xref ref-type="bibr" rid="article-157399.r6">[6]</xref><xref ref-type="bibr" rid="article-157399.r21">[21]</xref><xref ref-type="bibr" rid="article-157399.r22">[22]</xref>&#x000a0;One study's results reported changes in volumetric magnetic resonance imaging scans, showing enlargements of the caudate nucleus, putamen, and globus pallidus in patients with PANDAS, with subsequent normalization after successful treatment with therapeutic plasmapheresis.<xref ref-type="bibr" rid="article-157399.r19">[19]</xref>&#x000a0;While few studies have reported a good response and tolerance with no adverse reactions after courses of apheresis treatment in individuals with PANDAS/PANS, these studies typically had small sample sizes. These studies also failed to identify specific populations with anti-neuronal antibodies that would predict a response to therapeutic plasma exchange.<xref ref-type="bibr" rid="article-157399.r20">[20]</xref><xref ref-type="bibr" rid="article-157399.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Immunosuppressants</bold>
</p>
        <p>Immunosuppressant agents (eg, mycophenolate or rituximab) are also being researched.&#x000a0;</p>
      </sec>
      <sec id="article-157399.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most children fully recover from PANDAS. Studies investigating the efficacy of antibiotics in PANDAS management have results concluding that antibiotics are effective in reducing OCD symptoms regardless of evidence of infection. Additionally, other study results have shown improvement in neurological symptoms, particularly within 3 to 5 months of antibiotic treatment. However, antibiotics have not been found to reduce tic symptoms and neuropsychiatric exacerbations significantly.<xref ref-type="bibr" rid="article-157399.r4">[4]</xref><xref ref-type="bibr" rid="article-157399.r9">[9]</xref><xref ref-type="bibr" rid="article-157399.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-157399.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Thorough investigations for PANDAS diagnosis are crucial because untreated or unrecognized manifestations of PANDAS could elevate the risk of persistent neuropsychiatric symptoms. These symptoms may include obsessive-compulsive manifestations, tics leading to subsequent handwriting difficulties, visual and motor impairments, sleep disruptions, and anxiety disorders that persist into adulthood. Furthermore, some individuals may experience worsening symptoms after each streptococcal infection.</p>
      </sec>
      <sec id="article-157399.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Severe neuropsychiatric and behavioral manifestations are observed in these vulnerable pediatric populations, including suicidality, severe aggression, restrictive eating patterns, and profound sleep dysfunction and deprivation. Therefore, families must be&#x000a0;actively involved in the holistic management of patients with PANDAS and PANS.</p>
      </sec>
      <sec id="article-157399.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Awareness of this syndrome and its temporal association with streptococcal infections and other types of infection is crucial for promptly recognizing patients with PANDAS and PANS to ensure that potentially life-saving medical interventions are not delayed. This necessitates the involvement of multiple specialties and interprofessional management, starting from pediatricians and primary care clinicians in outpatient, inpatient, and emergency settings. Appropriate referrals to neurologists, psychiatrists, rheumatologists, infectious disease specialists, and endocrinologists are critical for ruling out other potential diagnoses that overlap with PANDAS/PANS. A holistic approach to patient care is essential to prevent possible life-threatening events and permanent disabilities related to the syndrome.&#x000a0;Collaboration among the entire interprofessional team, including nurses, pharmacists, nutritionists, cognitive-behavioral therapists and counselors, and geneticists, will facilitate positive outcomes among these patients and their families, considering the traumatic experiences and stigma associated with their diagnosis. Long-term monitoring of the recurrence of neuropsychiatric symptoms is also significant.</p>
      </sec>
      <sec id="article-157399.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=157399&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=157399">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/child-health/pediatric-autoimmune-neuropsychiatric-disorders-associated-with-streptococcal-infections-pandas/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=157399">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/157399/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=157399">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-157399.s15">
        <title>References</title>
        <ref id="article-157399.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dop</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marcu</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Padureanu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Niculescu</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Padureanu</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (Review).</article-title>
            <source>Exp Ther Med</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">33363605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pankratz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feige</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Runge</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bechter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schiele</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Domschke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tebartz van Elst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nickel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Endres</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid findings in patients with obsessive-compulsive disorder, Tourette syndrome, and PANDAS: A systematic literature review.</article-title>
            <source>Brain Behav Immun</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>115</volume>
            <fpage>319</fpage>
            <page-range>319-332</page-range>
            <pub-id pub-id-type="pmid">37748568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uccella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sciarretta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Apruzzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calevo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mancardi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Veneselli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Grandis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>PANDAS and PANS: Clinical, Neuropsychological, and Biological Characterization of a Monocentric Series of Patients and Proposal for a Diagnostic Protocol.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2019</year>
            <month>May</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>305</fpage>
            <page-range>305-312</page-range>
            <pub-id pub-id-type="pmid">30724577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pallanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics for PANDAS? Limited Evidence: Review and Putative Mechanisms of Action.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2018</year>
            <month>May</month>
            <day>03</day>
            <volume>20</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29722936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nekrasova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Butov</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tourette syndrome or PANDAS-a&#x000a0;case report.</article-title>
            <source>Wien Med Wochenschr</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>171</volume>
            <issue>11-12</issue>
            <fpage>289</fpage>
            <page-range>289-292</page-range>
            <pub-id pub-id-type="pmid">32955635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chain</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mascaro-Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kawikova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stoner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea and Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>564</fpage>
            <pub-id pub-id-type="pmid">32670106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marazziti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palermo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Massa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beatino</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Pozza</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-Compulsive Disorder, PANDAS, and Tourette Syndrome: Immuno-inflammatory Disorders.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2023</year>
            <volume>1411</volume>
            <fpage>275</fpage>
            <page-range>275-300</page-range>
            <pub-id pub-id-type="pmid">36949315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frankovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooperstock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Latimer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Pasternack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thienemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
              <collab>PANS Collaborative Consortium</collab>
            </person-group>
            <article-title>Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">25325534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rigante</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bellando Randone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Falcini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical-Serological Characterization and Treatment Outcome of a Large Cohort of Italian Children with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute Neuropsychiatric Syndrome.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>608</fpage>
            <page-range>608-614</page-range>
            <pub-id pub-id-type="pmid">31140830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gagliano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanca</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2023</year>
            <volume>19</volume>
            <fpage>1221</fpage>
            <page-range>1221-1250</page-range>
            <pub-id pub-id-type="pmid">37251418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Frankovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Overview of Treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>562</fpage>
            <page-range>562-565</page-range>
            <pub-id pub-id-type="pmid">28722464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaughan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Rapid Eye Movement Sleep Abnormalities in Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).</article-title>
            <source>J Clin Sleep Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>15</day>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>1027</fpage>
            <page-range>1027-32</page-range>
            <pub-id pub-id-type="pmid">27166296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hajjari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oldmark</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fernell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jakobsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vinsa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thorsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monemi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stenlund</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fasth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furuhjelm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnels</surname>
                <given-names>J&#x000c5;</given-names>
              </name>
              <name>
                <surname>Gillberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children.</article-title>
            <source>BMC Psychiatry</source>
            <year>2022</year>
            <month>Aug</month>
            <day>06</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>535</fpage>
            <pub-id pub-id-type="pmid">35933358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Westwell-Roper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of pediatric acute-onset neuropsychiatric syndrome (PANS) in children and adolescents with eating disorders.</article-title>
            <source>J Eat Disord</source>
            <year>2022</year>
            <month>Dec</month>
            <day>13</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>194</fpage>
            <pub-id pub-id-type="pmid">36514161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Avanthika</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tummala</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Autoimmune Neuropsychiatric Disorders Associated With Group A Streptococci: Etiopathology and Diagnostic Challenges.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e27729</fpage>
            <pub-id pub-id-type="pmid">36106298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Orefici</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <chapter-title>Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Ferretti</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fischetti</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <source><italic>Streptococcus pyogenes</italic>: Basic Biology to Clinical Manifestations [Internet]</source>
            <publisher-name>University of Oklahoma Health Sciences Center</publisher-name>
            <publisher-loc>Oklahoma City (OK)</publisher-loc>
            <year>2016</year>
            <month>2</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">26866234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerardi</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Casadonte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>PANDAS and comorbid Kleine-Levin syndrome.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-8</page-range>
            <pub-id pub-id-type="pmid">25329605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dileepan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Knowland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Platt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bittner-Eddy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Southern</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Latimer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agalliu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells.</article-title>
            <source>J Clin Invest</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>303</fpage>
            <page-range>303-17</page-range>
            <pub-id pub-id-type="pmid">26657857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Grantz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Katsovich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>860</fpage>
            <page-range>860-867.e2</page-range>
            <pub-id pub-id-type="pmid">27663941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alquist</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange in adolescent and adult patients with autoimmune neuropsychiatric disorders associated with streptococcal infections.</article-title>
            <source>J Clin Apher</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>597</fpage>
            <page-range>597-599</page-range>
            <pub-id pub-id-type="pmid">36251457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wenck</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whetten</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pullman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sederoff</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>High-efficiency Agrobacterium-mediated transformation of Norway spruce (Picea abies) and loblolly pine (Pinus taeda).</article-title>
            <source>Plant Mol Biol</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>407</fpage>
            <page-range>407-16</page-range>
            <pub-id pub-id-type="pmid">10092170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-157399.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latimer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>L'Etoile</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seidlitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-5</page-range>
            <pub-id pub-id-type="pmid">25658452</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
